Search Results | MSF Science Portal

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2022-12-22 • New England Journal of Medicine

BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Journal Article

|

Research

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.

2022-12-07 • PLOS Global Public Health

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...

Technical Report

|

Policy Brief

MSF Access Campaign

2022-11-08

TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to ...

Journal Article

|

Research

Wharton-Smith A, Horter SCB, Douch E, Gray NSB, James N, et al.

2021-12-04 • Trials

BACKGROUND
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...

Conference Material

|

Video

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-06-07 • MSF Scientific Days International 2022

No abstract available.

Journal Blog

|

Perspective

Berry C

2022-05-10 • PLoS Blogs

Journal Article

|

Research

Berry C, du Cros PAK, Fielding K, Gajewski S, Kazounis E, et al.

2022-06-13 • Trials

BACKGROUND
Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...

Journal Article

|

Letter

Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L

2021-05-29 • Trials

When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...

Journal Blog

|

Perspective

Douch E

2018-11-09 • BMJ Opinion (blog)

Journal Blog

|

Perspective

Jain L

2022-06-29 • BMJ Opinion (blog)

Science Portal

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

DR-TB drugs under the microscope 2022

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

6 months TB treatment for (almost) all

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

TB research requires strong protections, innovation, and increased funding in response to COVID-19

Engaging communities in tuberculosis research: The experience of the TB-PRACTECAL trial

New, shorter treatments for drug resistant TB are a lifeline for people living through conflict